Entera Bio Ltd.

Greetings and welcome to Interrobio's first quarter 22 update conference call. At this time, all participants are in a listen-only mode. The question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. I would now like to turn the call over to Rich Cockrell of Investor Relations. Thank you. You may begin.

Good morning and welcome to the call. Joining me today are Spiros Dramas, our Chief Executive Officer, and Miranda Teledano, Chief Business Officer, Chief Financial Officer, and Head of Strategy. A press release announcing Interis financial and operating results for the first quarter ended March 31st, 2022, was issued on May 12th, 2022. For those of you who have not received it, it is available on the company's website in the investor section. at www.interrobio.com. Before we begin our prepared remarks, I would like to remind you that various statements the company makes during this call about future results in operations and financial positions are or interpretations of data from completed and ongoing trials, business strategy, and plans and objectives for the company's future operations are considered to be forward-looking statements within the meaning of the federal securities laws. Our forward-looking statements are based upon current expectations that involve risk, changes in circumstances, assumptions, and uncertainties. Specifically, developments related to the COVID-19 pandemic continue to evolve, and the extent to which the pandemic will impact us in the future will depend on the duration and magnitude of such impact, and on numerous factors that we may not be able to accurately predict. These risks are described more fully in the company's SEC filings and are available on the SEC EDGAR system and on the website. We encourage all investors to read the company's SEC filings. All information we provide on this call is provided only as of today, and we may undertake no obligation to update any forward-looking statements we may make on this call on account of new information, future events or otherwise. Finally, Please be advised that today's call is being recorded and webcast. I would now like to turn the call over to Spiros Jamos. Go ahead, Spiros.

Good morning, everyone. We're aiming to keep this call brief because we already circulated our earnings release last week. I am pleased to announce that joining me on the call today is Miranda Toledano. As we announced on Monday, Miranda, who has been a member of our board of directors since 2018, has now also become our chief business officer and chief financial officer. Miranda is an accomplished leader in biotechnology industry with almost 25 years of C-level strategic leadership and Wall Street experience. I believe that the company will benefit significantly with Miranda as part of our leadership team, and her strategic experience is a perfect fit as we progress with global partnership discussions and continued development of our proprietary oral delivery platform. I'm happy to introduce Miranda Toledano.